Literature DB >> 2071126

Comparison of vaginal flora after treatment with a clotrimazole 500 mg vaginal pessary or a fluconazole 150 mg capsule for vaginal candidosis.

F C Boag1, E T Houang, R Westrom, S M McCormack, A G Lawrence.   

Abstract

The effect of antifungal therapy on the vaginal microbial flora was studied in 23 patients suffering from culture-positive, symptomatic vaginal candidosis. They were randomly allocated to receive either a 500 mg clotrimazole vaginal pessary or a 150 mg fluconazole capsule. Quantitative microbiological examination was carried out on samples of vaginal secretions obtained prior, and at intervals up to 10 days after, treatment. No significant difference was found in the vaginal flora before or after therapy in individual patients or between the treatment groups. In patients with C glabrata or C krusei, the yeasts persisted longer in the vagina with poorer response to either of the medications.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2071126      PMCID: PMC1194678          DOI: 10.1136/sti.67.3.232

Source DB:  PubMed          Journal:  Genitourin Med        ISSN: 0266-4348


  7 in total

Review 1.  The treatment of vaginitis: Trichomonas, yeast, and bacterial vaginosis.

Authors:  D V Landers
Journal:  Clin Obstet Gynecol       Date:  1988-06       Impact factor: 2.190

2.  Recovery and identification of human genital tract mycoplasmas.

Authors:  D Taylor-Robinson; P M Furr
Journal:  Isr J Med Sci       Date:  1981-07

Review 3.  Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis.

Authors:  J D Sobel
Journal:  Am J Obstet Gynecol       Date:  1985-08-01       Impact factor: 8.661

4.  Clotrimazole (Bay b 5097): in vitro and clinical pharmacological studies.

Authors:  M A Burgess; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1972-12       Impact factor: 5.191

5.  Drug resistance in the opportunistic pathogens Candida albicans and Candida glabrata.

Authors:  D Kerridge; R O Nicholas
Journal:  J Antimicrob Chemother       Date:  1986-10       Impact factor: 5.790

6.  Epidemiology of vaginal Candida infection: significance of numbers of vaginal yeasts and their biotypes.

Authors:  F C Odds; C E Webster; V C Riley; P G Fisk
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1987-05       Impact factor: 2.435

7.  Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis.

Authors:  E T Houang; O Chappatte; D Byrne; P V Macrae; J E Thorpe
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

  7 in total
  6 in total

1.  Antifungal susceptibility testing of Candida spp. by relative growth measurement at single concentrations of antifungal agents.

Authors:  F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

Review 2.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

3.  Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis.

Authors:  G E Stein; N Mummaw
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

4.  Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush).

Authors:  Hayley J Denison; Julia Worswick; Christine M Bond; Jeremy M Grimshaw; Alain Mayhew; Shakila Gnani Ramadoss; Clare Robertson; Mary Ellen Schaafsma; Margaret C Watson
Journal:  Cochrane Database Syst Rev       Date:  2020-08-24

5.  New treatments for vulvovaginal candidiasis.

Authors:  S Faro
Journal:  Infect Dis Obstet Gynecol       Date:  1996

6.  Systemic vs. topical therapy for the treatment of Vulvovaginal Candidiasis.

Authors:  S Faro
Journal:  Infect Dis Obstet Gynecol       Date:  1994
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.